A lung biopsy through the chest wall uses a needle, guided by CT or ultrasound, to sample a lung nodule or mass. In a pooled analysis of 8,133 CT-guided core biopsies, air leaked around the lung in 25.3% and needed treatment in 5.6%. You are checked with a chest X-ray or scan afterwards. Contact a doctor if you become short of breath, have chest pain or cough up a lot of blood.
Source. Every clinical step rests on the Korean Society of Thoracic Radiology guideline (KSTR 2020; 39 graded recommendations adapted from earlier guidelines, Delphi consensus; grades A to D, evidence levels I, high, to IV, very low). The British Thoracic Society guideline (2003), CIRSE 2017 and the SIR 2019 and 2020 documents could not be read, so this page is one society's guideline with two comparators and a patient information page, not a survey of the field.
Before. Multidisciplinary discussion of the need for and site of biopsy (A, III); informed consent, without which biopsy is contraindicated, as it is for vascular lesions (A, III). Careful multidisciplinary risk-benefit assessment for respiratory failure or predicted FEV1 below 35%, mechanical ventilation, bleeding tendency or coagulopathy, pulmonary hypertension, a single lung, or an uncooperative patient (B, III). Check haematocrit, PT, APTT and platelets (A, II) and withhold anticoagulants (A, II). In its commentary KSTR notes that SIR rated lung biopsy a moderate bleeding risk procedure in 2012 and a high risk one in 2019 and, citing both documents, gives an INR below 1.5, a minimum platelet count of 70,000 per microlitre and the last one or two doses of low molecular weight heparin withheld; citing the 2019 document alone, it says clopidogrel may be withheld for five days and aspirin may not need to be. Neither SIR document could be read. The Chinese consensus (2018, ungraded) accepts platelets above 50 × 10⁹/L and INR below 1.5 but stops aspirin and clopidogrel for at least 7 days and replaces warfarin with low molecular weight heparin a week before. Where severe COPD is suspected: multidisciplinary discussion (A, III) and a lung function test (B, III). Planning CT of sufficient quality (A, II).
During. Fluoroscopic or CT-based guidance as the primary modality (A, II); ultrasound can be considered as the primary modality for subpleural lesions abutting the chest wall (A, II). The patient must hold a stable position and follow breathing instructions.
Rates. Meta-analysis of CT-guided core biopsy (Heerink 2017, 32 articles, 8,133 procedures): pneumothorax 25.3%, pneumothorax needing intervention 5.6%, pulmonary haemorrhage 18.0%, haemoptysis 4.1%; major complications 5.7% (95% CI 4.4 to 7.4). KSTR cites national surveys with pneumothorax in 15.0 to 35.0% and tube drainage in 3.1 to 6.6%.
After. Check for pneumothorax on a chest radiograph or the guidance modality (A, II); KSTR's commentary asks for an upright radiograph within a few hours and notes that more than 90% of pneumothoraces appear within 3 to 4 hours and most delayed ones within 24 hours. Chest tube according to the patient's status, the size of the pneumothorax and what is available (A, II). Haemoptysis: monitor vital signs, saturation and volume (A, II); biopsy side down for mild bleeding (A, II); oxygen and consideration of intubation for massive bleeding (A, II). Air embolism: oxygen at the highest concentration, hyperbaric if available (A, III). Large haemothorax: conservative management with surgical and interventional radiology input (A, III). KSTR sets no criteria for discharge; the Chinese consensus says low-risk outpatients may leave after four hours without abnormality once a chest radiograph has been reviewed, and follows up for at least 24 hours. For patients, Cancer Research UK (reviewed 2025) says a little blood in the spit for a few days can happen, and to contact the healthcare team if it does not go away or there is a lot, and a doctor for shortness of breath or chest pain.
The team doing your biopsy follows its own protocol, and that comes first.
Why: Some nodules are better watched, sampled through the airways or removed. The team weighs what a biopsy would change against its risks for this person.
“We recommend a multidisciplinary discussion to determine the necessity and site of the biopsy.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level III
Why: The guideline puts the overall complication rate at around 25% or higher and says most complications can be managed conservatively. The person having the biopsy decides whether the answer is worth that.
“It is mandatory to obtain informed consent from the patient with a sufficient explanation of the benefits and potential risks of the procedure”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021
Why: The guideline says people with severe lung disease are more vulnerable to respiratory failure if a pneumothorax or bleeding occurs, and that a ventilator raises the risk of pneumothorax and air embolism, so the decision is made case by case.
“We suggest that PTNB should be carefully considered in the following circumstances based on a multidisciplinary risk-benefit assessment.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade B, evidence level III
Why: A biopsy can bleed into the lung or along the needle track, so the blood's ability to clot is checked beforehand.
“We recommend checking hematocrit, prothrombin time, activated partial thromboplastin time, and platelet count before performing the biopsy.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: The guideline lists dual antiplatelet therapy among the risk factors for coughing up blood, and reports the SIR 2019 emphasis on weighing the risk of bleeding against the risk of a clot. Sources differ on the details (see variants).
“We recommend withholding anticoagulants before performing the biopsy.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: The guideline asks for clotting and the platelet count to be corrected as far as possible when its thresholds are not met.
“A moderate or higher risk of bleeding tendency and coagulation abnormalities should be corrected before the procedure”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021
Why: The guideline says people with severe COPD find it hard to hold their breath during the biopsy and are more vulnerable to respiratory failure if a pneumothorax or bleeding occurs.
“We recommend a multidisciplinary discussion before performing PTNB in patients suspected of having severe chronic obstructive pulmonary disease.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level III
Why: The scan shows the lesion, the airways and blood vessels around it, and the fissures and bullae to avoid, so the safest needle path can be planned. Contrast can show blood vessels within the lesion.
“We recommend obtaining chest CT images of sufficient quality for planning the biopsy, possibly with contrast enhancement.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: In the studies the guideline cites, ultrasound guidance had a lower complication rate and a shorter procedure than CT, with similar accuracy and no radiation.
“We recommend that ultrasonography can be considered as the primary guidance modality for subpleural pulmonary lesions abutting the chest wall.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: The guideline says the safety and success of the biopsy rely on the patient's cooperation.
“the patient must maintain a stable position and comply with breathing instructions during the procedure.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021
Why: The guideline reports more air leaks with emphysema, small or deep lesions and more passes through the lining of the lung, and asks for the number of punctures and the length of lung crossed to be kept to a minimum.
“We recommend assessing the risk of pneumothorax before performing a biopsy and minimizing the risk of pneumothorax during the procedure.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: A pneumothorax is the most frequent complication of a lung biopsy and may need draining, so it is looked for.
“We recommend evaluating the occurrence of pneumothorax using chest radiographs or the guidance modality by an interventionist after performing the biopsy.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: In the studies the guideline cites, more than nine in ten pneumothoraces had appeared within three to four hours.
“An upright chest radiograph should be obtained within a few hours after the biopsy to identify potential complications”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021
Why: In the studies the guideline cites, most delayed air leaks appeared within 24 hours of the biopsy.
“Patients should be informed of the risks of delayed pneumothorax after PTNB”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021
Why: This is the advice Cancer Research UK gives patients about a collapsed lung after a biopsy. The Chinese consensus also asks that outpatients be reminded to return without delay if they have any symptoms.
“Contact a doctor if you become short of breath or have chest pain.”
Why: The guideline names watching, drawing the air off and a chest tube as the options, and says the choice depends on the size of the leak, the patient's condition, such as underlying COPD, and their symptoms.
“We recommend determining the necessity of chest tube insertion by considering the status of the patient, amount of pneumothorax, and medical availability.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: The guideline says coughing up blood after a biopsy usually stops by itself but that heavy bleeding can develop, and that its severity is judged from the rate of bleeding and the patient's condition as well as the volume.
“When hemoptysis occurs, we recommend monitoring vital signs and blood oxygen saturation levels, along with assessing the amount of hemoptysis.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: Lying with the biopsied side down protects the other lung from the blood.
“In cases of mild hemoptysis, we recommend conservative management with biopsy-site-down positioning.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: The guideline says it is crucial to protect the airway and to keep the unaffected lung clear of blood.
“When massive hemoptysis occurs, we recommend supplying oxygen to maintain blood oxygen saturation, along with considering single-lumen endotracheal tube insertion.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level II
Why: The guideline calls oxygen at as high a concentration as possible the most important step: it relieves the lack of oxygen and helps clear the air.
“When systemic air embolism occurs, we recommend supplying oxygen at as high a concentration as possible, including hyperbaric oxygen therapy, and anticonvulsants, if needed.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level III
Why: The guideline reports haemothorax in 0.09 to 0.57% of biopsies. Where it is large or growing, it names CT angiography to look for an injured chest wall artery and embolisation as the first treatment for one.
“When a large amount of hemothorax occurs, we recommend conservative management, while contacting clinicians such as thoracic or general surgeons and interventional radiologists.”
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · recommendation grade A, evidence level III
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Of the guidelines that could be read, the Korean Society of Thoracic Radiology guideline (2020) is the most recent and the only one that grades its recommendations: a multidisciplinary decision, informed consent, clotting tests and a platelet count, anticoagulants withheld, CT planning, ultrasound guidance considered for lesions against the chest wall, a check for pneumothorax afterwards, a chest tube decided by the patient's condition and the size of the leak, and biopsy side down for haemoptysis. None of those is graded above evidence level II (moderate), and the guideline is an adaptation of earlier ones. Where the Chinese expert consensus (2018, ungraded) differs, both are shown. Thresholds: KSTR, citing the SIR 2012 and 2019 documents together, gives an INR below 1.5 and a minimum platelet count of 70,000 per microlitre; the Chinese consensus accepts platelets above 50 × 10⁹/L with the same INR. Antiplatelets: KSTR reports from SIR 2019 that clopidogrel may be withheld for five days and that aspirin may not need to be; the Chinese consensus stops both for at least 7 days. Observation: KSTR asks for a radiograph or a check on the guidance modality, with an upright radiograph within a few hours; the Chinese consensus scans immediately, says low-risk outpatients may leave after four hours without abnormality and recommends a radiograph within 24 hours. The British Thoracic Society guideline (2003), the CIRSE 2017 guideline, the SIR 2012 and 2019 documents themselves and the SIR 2020 quality standards could not be read, so this is not a full comparison: their positions are absent, or appear only as KSTR reports them.
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · Chinese Society of Interventional Oncology, Chinese Anti-Cancer Association (Thoracic Cancer; Guo et al.) 2018
Where it differs: KSTR 2020 notes that SIR rated lung biopsy a moderate bleeding risk procedure in 2012 and a high risk one in 2019. Citing both documents it gives an INR below 1.5, a minimum platelet count of 70,000 per microlitre, and "Regarding low-molecular weight-heparin, the last 1 or 2 doses need to be withheld". Citing the 2019 document it reports that clopidogrel may be withheld for five days and that aspirin may not need to be. Chinese consensus 2018: warfarin replaced by low molecular weight heparin a week before, with the heparin stopped 24 hours before; aspirin and clopidogrel stopped for at least 7 days; biopsy only with platelets above 50 × 10⁹/L and INR below 1.5; and bevacizumab, as an example of an anti-angiogenic drug, stopped 6 weeks before.
Evidence: KSTR grades withholding anticoagulants A, evidence level II, but takes the numbers from SIR without grading them (the SIR documents were not read, so whether the 2019 edition prints the same figures as the 2012 one is not confirmed here), and lists dual antiplatelet therapy among the reported risk factors for haemoptysis. The Chinese consensus is ungraded. Neither addresses the direct oral anticoagulants by name in the text read; those timings are in the perioperative protocols linked from this page.
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · Chinese Society of Interventional Oncology, Chinese Anti-Cancer Association (Thoracic Cancer; Guo et al.) 2018
Where it differs: KSTR recommends a check for pneumothorax on a radiograph or the guidance modality and, in its commentary, an upright radiograph within a few hours; it sets no observation time and no criteria for discharge. Chinese consensus: a full chest CT immediately after the biopsy; for people judged low risk beforehand, biopsy as an outpatient may be considered, and they may leave after four hours without abnormality once a chest radiograph has been reviewed; a radiograph within 24 hours and follow-up for at least 24 hours.
Evidence: KSTR: "More than 90% of all pneumothoraces appeared within 3 to 4 hours of the PTNB, and most of the delayed pneumothoraces occurred within 24 hours after the procedure". KSTR's recommendation is grade A, evidence level II; the Chinese consensus is ungraded. No randomised comparison of observation times is cited in either text.
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · Chinese Society of Interventional Oncology, Chinese Anti-Cancer Association (Thoracic Cancer; Guo et al.) 2018
Where it differs: The measures studied are rolling the patient onto the biopsied side as the needle comes out, and sealing the track with saline, a plug or the patient's own blood. KSTR reports the studies in its commentary without making a graded recommendation on them, and adds that one study found fewer pneumothoraces with the patient positioned biopsy side down. The Chinese consensus says it is not known whether sealing the track with gel, gelatin sponge or saline reduces pneumothorax.
Evidence: KSTR: "A recent meta-analysis reported that normal saline tract sealant, a rapid needle-out patient-rollover approach (74), and the use of a tract plug or blood patch reduced the likelihood of pneumothorax requiring tube drainage (75)." The studies behind that sentence were not read for this page.
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · Chinese Society of Interventional Oncology, Chinese Anti-Cancer Association (Thoracic Cancer; Guo et al.) 2018
Where it differs: KSTR sets no size threshold: the need for a chest tube is decided from the patient's status, the amount of pneumothorax and what is available. The Chinese consensus says a small, asymptomatic, stable pneumothorax needs no special treatment, and that a chest tube should be inserted if the pneumothorax exceeds 30%, keeps growing or causes severe symptoms.
Evidence: KSTR's recommendation is grade A, evidence level II. The Chinese consensus is ungraded and cites no comparison for its 30% figure in the passage read.
Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 · Chinese Society of Interventional Oncology, Chinese Anti-Cancer Association (Thoracic Cancer; Guo et al.) 2018
Where it differs: A cutting (core) needle gives a strip of tissue for histology and molecular testing; fine needle aspiration gives cells. KSTR leaves the choice to the operator, by the availability of a cytopathologist, the risk of malignancy, the lesion size, the tissue needed and the operator's experience (grade A, evidence level II), and recommends biopsy to obtain tissue for molecular profiling of lung cancer (grade A, evidence level I).
Evidence: Heerink 2017 pooled overall complication rates of 38.8% (95% CI 34.3 to 43.5%) for core biopsy and 24.0% (95% CI 18.2 to 30.8%) for fine needle aspiration, and major complication rates of 5.7% (95% CI 4.4 to 7.4%) and 4.4% (95% CI 2.7 to 7.0%). Most of the difference was in minor complications: pneumothorax not needing treatment, bleeding seen only on the scan, and brief haemoptysis.
European Radiology (Heerink et al.) 2017 · Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Assess the risks and benefits of a biopsy before performing it “We recommend assessing the risks and benefits of a biopsy procedure before performing the biopsy.” | recommendation grade A, evidence level II | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Absolute contraindications: no informed consent, or a vascular lesion of the lung “We recommend not performing a biopsy in the following circumstances, which are absolute contraindications.” | recommendation grade A, evidence level III | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Withhold anticoagulants before biopsy | recommendation grade A, evidence level II | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Lung function test before biopsy where severe COPD is suspected “We suggest performing a pre-procedural pulmonary function test in patients suspected of having severe chronic obstructive pulmonary disease.” | recommendation grade B, evidence level III | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Fluoroscopic or CT-based guidance as the primary modality “We recommend primary utilization of fluoroscopic or CT-based guidance modalities for the biopsy, including cone-beam CT and CT fluoroscopy.” | recommendation grade A, evidence level II | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Biopsy to obtain tissue for molecular profiling of lung cancer or intrathoracic metastasis “We recommend performing a biopsy to acquire a tumor specimen for molecular profiling of lung cancer or intrathoracic metastasis.” | recommendation grade A, evidence level I | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Sensitivity above 85% and specificity above 90% for malignancy as the standard a unit should reach “We recommend that the sensitivity and specificity of the biopsy for malignancy should be higher than 85% and 90%, respectively.” | recommendation grade A, evidence level II | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Check for pneumothorax after the biopsy on a radiograph or the guidance modality | recommendation grade A, evidence level II | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Chest tube decided by the patient's status, the amount of pneumothorax and availability | recommendation grade A, evidence level II | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Biopsy side down for mild haemoptysis | recommendation grade A, evidence level II | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| High-concentration oxygen, including hyperbaric oxygen, for systemic air embolism | recommendation grade A, evidence level III | Korean Society of Thoracic Radiology (Korean Journal of Radiology; Yoon et al.) 2021 |
| Pooled rates for CT-guided core biopsy: pneumothorax 25.3%, pneumothorax needing intervention 5.6%, pulmonary haemorrhage 18.0%, haemoptysis 4.1% “For CT-guided core biopsy the pooled rate of pneumothorax was 25.3 %, of pneumothorax requiring intervention 5.6 %, of pulmonary haemorrhage 18.0 %, and of hemoptysis 4.1 %.” | Meta-analysis of observational studies (not graded) | European Radiology (Heerink et al.) 2017 |
Shares Blood thinners around cancer surgery, biopsy and endoscopy: when to stop, whether to bridge, when to restart, Anticoagulants and antiplatelet drugs around elective endoscopy and endoscopic biopsy.
Shares Haemoptysis (coughing up blood), Diagnostic flexible bronchoscopy and EBUS: preparation, sedation and aftercare, Core needle biopsy and fine-needle aspiration (FNA), Lung cancer (all types).
Shares Haemoptysis (coughing up blood), Pulmonary nodule, CT (computed tomography), Lung cancer (all types).
Shares Pulmonary nodule, CT (computed tomography), Lung cancer (all types).
Shares Haemoptysis (coughing up blood), CT (computed tomography), Lung cancer (all types).
Shares Core needle biopsy and fine-needle aspiration (FNA), Biopsy.
Shares Diagnostic flexible bronchoscopy and EBUS: preparation, sedation and aftercare, CT (computed tomography), Lung cancer (all types).
Shares Pulmonary nodule, CT (computed tomography), Lung cancer (all types).